Open an account

Virax Biolabs Group

VRAX · NASDAQ

$1.22−$0.015 (−1.21%)TodayMarket closed ·
Prev close $1.23

About VRAX

Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The firm is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The firm is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).

Employees
19
Headquarters
London
Listed
Jul 14, 2022
Sector
Health Care
Industry
Health Care Providers & Services
Website
viraxbiolabs.com

VRAX key statistics

Market cap
1.77M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
205.02K
Volume
33.99K
Open price
$1.24
High today
$1.27
Low today
$1.20
52 Week high
$21.75
52 Week low
$1.15

Virax Biolabs Group (VRAX) at a glance

Virax Biolabs Group (VRAX) last traded at $1.22, with a market cap of 1.77M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.20 and $1.27. The current price is 1.7% above the day's low and 3.6% below its high.

Volume so far is 33.99K shares, below the average of 205.02K shares a day.

Over the past year Virax Biolabs Group has ranged from $1.15 to $21.75, and now sits 0% of the way up that range.

The average analyst price target is $25.50, 1990.2% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $25.50
Low
$25.25
Now
$1.22
High
$26.25

VRAX news

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Press releasePRNewswire

    Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

  • Press releasePRNewswire

    Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

  • Avi Kapoor

    Dow Gains 50 Points; Simulations Plus Earnings Top Views

  • Press releaseGlobe Newswire

    These Companies Just Dropped Major Growth Catalysts

  • Avi Kapoor

    US Stocks Edge Higher; Delta Air Lines Posts Upbeat Q2 Earnings

  • Press releasePRNewswire

    Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.